Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 338

Similar articles for PubMed (Select 11015817)

1.

Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

Essock SM, Frisman LK, Covell NH, Hargreaves WA.

Arch Gen Psychiatry. 2000 Oct;57(10):987-94.

PMID:
11015817
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

5.

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D.

Arch Gen Psychiatry. 1999 Jun;56(6):565-72.

PMID:
10359474
6.
7.
8.
9.

A cost-effectiveness clinical decision analysis model for schizophrenia.

Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE.

Am J Manag Care. 1998 Mar;4(3):345-55.

10.

Clozapine eligibility among state hospital patients.

Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L.

Schizophr Bull. 1996;22(1):15-25.

11.

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

Essock SM, Hargreaves WA, Covell NH, Goethe J.

Psychopharmacol Bull. 1996;32(4):683-97.

PMID:
8993092
12.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators.

Am J Psychiatry. 2006 Dec;163(12):2080-9.

PMID:
17151158
13.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
14.
15.

Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.

Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR.

Can J Clin Pharmacol. 2001 Winter;8(4):199-206.

PMID:
11743592
16.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
17.

Assessing cost-effectiveness of drug interventions for schizophrenia.

Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):44-54.

PMID:
15660705
18.

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B.

Am J Psychiatry. 1993 Nov;150(11):1630-8.

PMID:
8105705
19.

Health status and health care costs for publicly funded patients with schizophrenia started on clozapine.

Blieden N, Flinders S, Hawkins K, Reid M, Alphs LD, Arfken CL.

Psychiatr Serv. 1998 Dec;49(12):1590-3.

PMID:
9856622
20.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk